SAN DIEGO, Sept. 24, 2015 /PRNewswire/ -- aTyr Pharma,
Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the
discovery and development of Physiocrine-based therapeutics to
address severe rare diseases, today announced participation in two
upcoming international scientific conferences:
International World Muscle (WMS) Congress 2015, Brighton, UK
September 30 – October 4, 2015
- Resolaris, a potential therapeutic for rare myopathies with
an immune
component.
(Guided Poster Session 1- October 1;
14:30-16:00 GMT)
- Author and Presenter: Dr. John
McKew, VP Research, aTyr Pharma
- Supporting Authors: M. Ashlock, K. Ogilvie, L. Nangle, K.
Taylor, K. Chiang, E. Mertsching, J. Chang, K. Moldt, C.
Polizzi, Z. Xu, C. Lo, C. Lau, R. Adams, E. Chong
10th Annual International Symposium on
Aminoacyl-tRNA Synthetases (AARS2015), Barcelona, Spain
October 18 – 22, 2015
- Utilizing "Omics" to Unlock Aminoacyl-tRNA Synthetase
Therapeutic Potential.
(Session V: Pharma & Biotech-
October 21; 14:20-16:00 CEST)
- Author and Presenter: Dr. Leslie
Nangle, Associate Director, Discovery Biology, aTyr
Pharma
- Supporting Authors: R. Adams, K. Chiang, Y. Chong, W. Lo, Z.
Xu, X. Yang, J. McKew, P. Schimmel, J. Mendlein
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of
innovative medicines for patients suffering from severe rare
diseases using its knowledge of Physiocrine biology, a newly
discovered set of physiological modulators. The Company's lead
candidate, Resolaris™, is a first-in-class intravenous protein
therapeutic for the treatment of rare myopathies with an immune
component. Resolaris™ is currently in a Phase 1b/2 clinical trial
in adult patients with facioscapulohumeral muscular dystrophy
(FSHD). Trials are planned in additional indications, including
early onset FSHD and limb-girdle muscular dystrophy (LGMD) 2B.
Trials are also planned for indications in interstitial lung
disease (ILD). To protect this pipeline, aTyr built an intellectual
property estate comprising 45 issued or allowed patents and over
240 pending patent applications that are solely owned or
exclusively licensed by aTyr. aTyr's key programs are currently
focused on severe, rare diseases characterized by immune
dysregulation for which there are currently limited or no treatment
options. For more information, please visit
http://www.atyrpharma.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/atyr-pharma-announces-presentations-at-the-world-muscle-congress-and-10th-international-symposium-on-aminoacyl-trna-synthetases-aars2015-300148367.html
SOURCE aTyr Pharma, Inc.